These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37484224)

  • 1. The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities.
    Deng L; Wang L; Zhang J; Zhao L; Meng Y; Zheng J; Xu W; Zhu Z; Huang H
    Heliyon; 2023 Jun; 9(6):e16922. PubMed ID: 37484224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
    Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
    Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
    Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
    Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy.
    Guo XF; Zhang YY; Kang J; Dou QH; Zhu XF
    J Drug Target; 2022 Mar; 30(3):302-312. PubMed ID: 34319822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
    Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
    J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
    Kudo K; Ohashi K; Makimoto G; Higo H; Kato Y; Kayatani H; Kurata Y; Takami Y; Minami D; Ninomiya T; Kubo T; Ichihara E; Sato A; Hotta K; Yoshino T; Tanimoto M; Kiura K
    Mol Oncol; 2017 Jun; 11(6):670-681. PubMed ID: 28388009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
    Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
    Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL
    MAbs; 2015; 7(5):931-45. PubMed ID: 26073904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
    Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.